<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188015</url>
  </required_header>
  <id_info>
    <org_study_id>ANX007-GLA-02</org_study_id>
    <nct_id>NCT04188015</nct_id>
  </id_info>
  <brief_title>Study of ANX007 in Participants With Primary Open-angle Glaucoma</brief_title>
  <official_title>A Phase 1b, Randomized, Double-masked, Sham-controlled Study of ANX007 Administered as Intravitreal Injections to Assess Safety and Tolerability in Participants With Primary Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-masked, randomized, sham-controlled study evaluating two dose levels of
      ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary
      Open-angle Glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1b, double-masked, sham-controlled study evaluating 2 dose levels of ANX007
      administered as 2 IVT injections separated by 4 weeks. Approximately 15-29 subjects will be
      enrolled. An interim analysis of the initial set of 15 participants may be conducted. Based
      on this analysis, an additional 10-14 participants may be enrolled at a 1:1 ratio to receive
      one of the two dose levels.

      The primary objective is to evaluate the safety and tolerability of repeat IVT injections of
      ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate
      the anterior chamber fluid pharmacokinetics (PK) of ANX007, PD effect of ANX007 on anterior
      chamber fluid C1q activity, and immunogenicity. An exploratory objective will evaluate ocular
      PD effect of ANX007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Actual">June 3, 2019</completion_date>
  <primary_completion_date type="Actual">June 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of ANX007 in participants with primary open-angle glaucoma as measured by occurrence of treatment-emergent adverse events.</measure>
    <time_frame>Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate PK parameters of ANX007 in serum after repeat injections</measure>
    <time_frame>Day 29</time_frame>
    <description>Maximum Serum Concentration (Cmax) of ANX007</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PK parameters of ANX007 in serum after repeat injections</measure>
    <time_frame>Day 29</time_frame>
    <description>Area Under the Curve (AUC) of ANX007</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PK parameters of ANX007 in aqueous humor after repeat intravitreal injections</measure>
    <time_frame>Day 29</time_frame>
    <description>Maximum aqueous humor Concentration (Cmax) of ANX007</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PK parameters of ANX007 in aqueous humor after repeat intravitreal injections</measure>
    <time_frame>Day 29</time_frame>
    <description>Aqueous humor Area Under the Curve (AUC) of ANX007</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PD parameters of ANX007 in aqueous humor after repeat intravitreal injections</measure>
    <time_frame>Day 29</time_frame>
    <description>Maximum C1q concentration (Cmax) in aqueous humor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PD parameters of ANX007 in aqueous humor after repeat intravitreal injections</measure>
    <time_frame>Day 29</time_frame>
    <description>C1q area under the curve (AUC) in aqueous humor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PD parameters of ANX007 in serum after repeat intravitreal injections</measure>
    <time_frame>Day 29</time_frame>
    <description>Maximum C1q concentration (Cmax) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PD parameters of ANX007 in serum after repeat intravitreal injections</measure>
    <time_frame>Day 29</time_frame>
    <description>C1q concentration area under the curve (AUC) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of ANX007 as measured by serum anti-drug antibodies (ADA) after repeat intravitreal injections of ANX007</measure>
    <time_frame>Day 84</time_frame>
    <description>Incidence of positive antibody titre against ANX007 in serum</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>2.5mg ANX007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 in every 3 subjects will be randomized to 2.5mg dose of ANX007.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.0mg ANX007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 in every 3 subjects will be randomized to 5.0mg dose of ANX007.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>1 in every 3 subjects will have a sham procedure performed instead of receiving ANX007.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2.5mg ANX007</intervention_name>
    <description>A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.</description>
    <arm_group_label>2.5mg ANX007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>5.0mg ANX007</intervention_name>
    <description>A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.</description>
    <arm_group_label>5.0mg ANX007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.</description>
    <arm_group_label>Sham Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female age 18 years, and above.

          2. Diagnosis of primary open-angle glaucoma.

          3. Ability to perform a reliable visual field test in the study eye with a cutoff of 33%
             for fixation losses and 33% for false-positive response rates.

          4. Intraocular pressure (IOP) &lt;21 mm Hg at screening and Day 1.

          5. The IOP treatment regimen in the study eye should be stable for at least 4 weeks prior
             to injection, with no change in the IOP treatment regimen anticipated throughout study
             participation.

          6. Ability to comply with the requirements of the study and complete the full sequence of
             protocol specified injections, procedures, and evaluations.

        Exclusion Criteria:

          1. Extensive glaucomatous visual-field damage with a mean deviation worse than -18 dB on
             Humphrey visual field testing.

          2. Any current or prior ocular pathology, other than glaucoma, which could interfere with
             the conduct of the study including, but not limited to, retinal or optic nerve disease
             and media opacity in the study eye.

          3. History of intraocular inflammatory or infectious eye disease in the study eye.

          4. Ocular trauma in the study eye within the preceding 6 months.

          5. A history of uncomplicated cataract surgery less than 3 months prior to injection, or
             trabeculectomy, iridotomy, or other ocular procedures in the study eye that could
             affect drug distribution and excretion.

          6. Any abnormality preventing reliable tonometry in the study eye.

          7. Concurrent use of glucocorticoid medications administered by any ocular or systemic
             route. Nasal, inhaled, and dermatologic (if not administered around the eyes)
             glucocorticoids are permitted.

          8. Receiving monoamine oxidase inhibitor therapy or patient-reported hypersensitivity to
             any component of apraclonidine, brimonidine, clonidine, phenylephrine, povidone
             iodine, proparacaine, or ANX007.

          9. Active or history of malignancy within the past 5 years with the exception of
             curatively treated, basal cell carcinoma.

         10. Previous treatment with another humanized monoclonal antibody, Fab or Fab'2.

         11. History of any autoimmune or neurologic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Humphriss</last_name>
    <role>Study Director</role>
    <affiliation>Annexon Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.annexonbio.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

